Companies / Switzerland
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Novartis Expands Anti-Infectives Pipeline With Protez Acquisition
June 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Swiss pharmaceutical giant Novartis is to acquire US antibiotic developer Protez Pharmaceuticals in a deal worth up to US$400mn. Protez will become an independently-run subsidiary of the Swiss firm. The deal is structured as an initial US$100mn payment, followed by further payments of up to US$300mn depending on whether certain clinical milestones, regulatory approvals and commercial targets are